RFK Jr. eases access to unproven peptides despite opposition from FDA scientists
HHS announced temporary enforcement discretion for compounding involving six peptides while FDA rulemaking continues.
TL;DR
- On October 28, the Department of Health and Human Services issued an interim policy directing enforcement discretion for certain pharmacies and clinicians compounding six peptide substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The Federal Register notice describes the policy as temporary while the agency considers the substances under its compounding rules.
- The Associated Press reported that FDA scientific staff had limited input and opposed the change, citing people familiar with the policy’s development.
- Ars Technica reported that the policy does not amount to FDA approval of the compounded products.
On October 28, the Department of Health and Human Services issued an interim policy directing enforcement discretion for certain pharmacies and clinicians compounding six peptide substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The Federal Register notice describes the policy as temporary while the agency considers the substances under its compounding rules. [1] [2]
The Associated Press reported that FDA scientific staff had limited input and opposed the change, citing people familiar with the policy’s development. The report says the approach avoids formally adding the peptides to the list of bulk substances that pharmacies may compound. [1] [2]
Ars Technica reported that the policy does not amount to FDA approval of the compounded products. The HHS notice likewise says enforcement discretion is not a determination that a compounded drug is approved, safe or effective. [1] [2]
The policy leaves unresolved how long enforcement discretion will remain in place and what final action FDA will take. The cited reporting describes a regulatory shift, not clinical evidence establishing efficacy or safety for any of the six substances. [1] [2]
Why it matters
The change alters near-term enforcement exposure for compounding businesses while leaving product approval and evidence questions unresolved. It is a regulatory development, not a clinical finding.
Editor's note
No treatment or consumer recommendation is implied. HHS policy language and AP/Ars reporting are the basis; the policy does not establish safety or efficacy. TODO-review: ‘enforcement discretion’ is rendered as ‘단속 재량’.